{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Winter SS"],"funding":["NCI NIH HHS"],"pagination":["585-589"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8791581"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(2)"],"pubmed_abstract":["Immunotherapies directed against B-cell surface markers have been a common developmental strategy to treat B-cell malignancies. The immunoglobulin heavy chain surrogate light chain (SLC), comprising the VpreB1 (CD179a) and Lamda5 (CD179b) subunits, is expressed on pro- and pre-B cells, where it governs pre-B-cell receptor (BCR)-mediated autonomous survival signaling. We hypothesized that the pre-BCR might merit the development of targeted immunotherapies to decouple \"autonomous\" signaling in B-lineage acute lymphoblastic leukemia (B-ALL). We used the Children's Oncology Group (COG) minimal residual disease (MRD) flow panel to assess pre-BCR expression in 36 primary patient samples accrued to COG standard- and high-risk B-ALL studies through AALL03B1. We also assessed CD179a expression in 1"],"journal":["Blood advances"],"pubmed_title":["VpreB surrogate light chain expression in B-lineage ALL: a report from the Children's Oncology Group."],"pmcid":["PMC8791581"],"funding_grant_id":["P30 CA021765","U10 CA180886","R35 CA197695","U10 CA180899","U24 CA196173"],"pubmed_authors":["Qu C","Wilson BS","Carroll AJ","Mullighan CG","Simeona N","Winter SS","Heerema NA","Gheorghe G","McCaustland A","Wood BL"],"additional_accession":[]},"is_claimable":false,"name":"VpreB surrogate light chain expression in B-lineage ALL: a report from the Children's Oncology Group.","description":"Immunotherapies directed against B-cell surface markers have been a common developmental strategy to treat B-cell malignancies. The immunoglobulin heavy chain surrogate light chain (SLC), comprising the VpreB1 (CD179a) and Lamda5 (CD179b) subunits, is expressed on pro- and pre-B cells, where it governs pre-B-cell receptor (BCR)-mediated autonomous survival signaling. We hypothesized that the pre-BCR might merit the development of targeted immunotherapies to decouple \"autonomous\" signaling in B-lineage acute lymphoblastic leukemia (B-ALL). We used the Children's Oncology Group (COG) minimal residual disease (MRD) flow panel to assess pre-BCR expression in 36 primary patient samples accrued to COG standard- and high-risk B-ALL studies through AALL03B1. We also assessed CD179a expression in 1","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-05-28T23:33:44.508Z","creation":"2022-02-11T15:57:22.864Z"},"accession":"S-EPMC8791581","cross_references":{"pubmed":["34662891"],"doi":["10.1182/bloodadvances.2021005245"]}}